MAP2K1 and pancreatic neoplasm: In one study, synergism between SRC inhibitors (e.g., dasatinib, PP2) and a MEK1/2 inhibitor (pimasertinib) enhanced sensitivity to gemcitabine in the squamous subtype of pancreatic cancer cells (e.g., SW1990 and BxP3) and not in PDAC progenitor cells (e.g., AsPC1) [208].